1143579-99-0

Upstream product

• 1143579-97-8 methyl 3-ethynyl-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylate 

Downstream Products

• 1216934-25-6 C₃₀H₂₈N₆O₅ 
• 1216934-19-8 3-(1-(2-(biphenyl-4-ylamino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylic acid 
• 1216934-27-8 C₂₇H₂₀N₆O₄S 
• 1143579-78-5 3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylic acid 
• 1216934-20-1 3-(1-(4-(biphenyl-4-ylamino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylic acid 
• 1216934-21-2 6-hydroxy-1-methyl-3-(1-(3-oxo-3-(phenylamino)propyl)-1H-1,2,3-triazol-4yl)-2-phenyl-1H-indole-5-carboxylic acid 

Relevant academic research and scientific papers

Salicylic acid based small molecule inhibitor for the oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)

The Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) plays a pivotal role in growth factor and cytokine signaling. Gain-of-function SHP2 mutations are associated with Noonan syndrome, various kinds of leukemias, and solid tumors. Thus, there is considerable interest in SHP2 as a potential target for anticancer and antileukemia therapy. We report a salicylic acid based combinatorial library approach aimed at binding both active site and unique nearby subpockets for enhanced affinity and selectivity. Screening of the library led to the identification of a SHP2 inhibitor II-B08 (compound 9) with highly efficacious cellular activity. Compound 9 blocks growth factor stimulated ERK1/2 activation and hematopoietic progenitor proliferation, providing supporting evidence that chemical inhibition of SHP2 may be therapeutically useful for anticancer and antileukemia treatment. X-ray crystallographic analysis of the structure of SHP2 in complex with 9 reveals molecular determinants that can be exploited for the acquisition of more potent and selective SHP2 inhibitors.